Skip to main content

Advertisement

Table 2 P-RFA vs. PEI: Results of meta-analysis

From: Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma

Variables No. of studies furnishing data Results RR/WMD (95% CI) P-value I2
   RFA PEI   
Baseline characteristics:      
Child-Pugh grade of liver dysfunction
A
B
624,26–30
624,26–30
71%
24%
70%
26%
1.05 (0.97, 1.13), 0.44
0.92 (0.74, 1.15), 0.43
0%
0%
Tumour size, cm (mean ± SEM) 426–28,30 2.62 ± 0.33 2.47 ± 0.35 0.13 (0.01, 0.25),0.03 0%
Single nodule 624,26–30 59% 55% 1.04 (0.94, 1.50), 0.44 17%
Follow-up duration, months (mean ± SEM) 326–28 25 ± 6.2 23.6 ± 5.6 0.97 (-1.32, 3.3), 0.4 0%
Efficacy:      
Survival
1 year
2 years
3 years
4 years
526–30
526–30
427–30
229,30
96%
86%
73%
62%
91%
75%
58%
51%
1.04 (1.007, 1.08), 0.02
1.13 (1.06, 1.20), <0.001
1.28 (1.12, 1.45), <0.001
1.24 (1.05,1.48), <0.001
0%
0%
12.6%
0%
Local recurrence 426–29 7% 22% 0.37 (0.23, 0.59), 0.000 0%
Disease-free survival
1 year
2 years
3 years
326–28
326–28
227,28
80%
61%
40%
70%
42%
19%
1.13 (1, 1.28), 0.04
1.31 (1.06, 1.61), 0.013
2.1 (1.35, 3.23), 0.001
0%
0%
0%
Tumour complete response 424,26–28 93.5% 84.5% 1.10 (1.04, 1.17), 0.01 0%
Remote intra-hepatic recurrence 526–30 43% 45% 0.97 (0.82, 1.11), 0.56 0%
Safety:      
Total complications 624,26–30 19.2% 10.5% 2.55 (1.8, 3.65), <0.001 0%
Major complications 424,28–30 4.1% 2.7% 1.85 (0.68, 5.01); 0.22 0%
  1. RR: Relative risk. WMD: Weighted mean difference. All based on random effects meta-analysis.